国际泌尿病理学会膀胱癌共识会议第4工作组:膀胱癌分子亚型分类原则与新兴临床价值
2022年国际泌尿病理学会膀胱癌共识会议第4工作组综述了膀胱癌分子亚型的分类系统,提出7项原则总结进展与挑战,并指出目前数据不足以支持常规分子亚型指导临床管理。
要点
- 膀胱癌有三大分子亚型:luminal、basal-squamous和neuroendocrine。
- 分子亚型间边界模糊,不同系统对临界病例分类常不一致。
- 当前数据不足以支持常规分子亚型指导膀胱癌临床管理。
核心结论
- 数据目前不足以支持常规使用分子亚型指导膀胱癌管理,多数会议参与者持相同观点。
- 分子亚型不应视为肿瘤的内在属性,而应视为特定实验室检测、平台和分类算法的结果,并需针对特定临床应用进行验证。
研究设计与样本
- 2022年国际泌尿病理学会膀胱癌共识会议第4工作组对膀胱癌分子亚型科学现状进行综述。
主要发现
- 膀胱癌有3个主要分子亚型:luminal、basal-squamous和neuroendocrine。
- 肿瘤微环境特征在膀胱癌间差异很大,尤其在luminal肿瘤中。
- luminal膀胱癌生物学多样,部分源于FGFR3信号和RB1失活等非微环境因素。
- 分子亚型与肿瘤分期和组织形态学相关。
- 许多分型系统包含特有问题,如其他系统未识别的亚型;亚型间边界模糊,临界病例常被不同系统分类不同;同一肿瘤内组织形态不同区域的分子亚型常不一致。
临床怎么用
- 分子亚型作为临床生物标志物有前景,但当前不推荐常规用于指导膀胱癌管理。
- 应用分子亚型时应明确其检测平台、分类算法及针对特定临床应用的验证情况。
局限性
- 数据目前不足以支持分子亚型的常规临床使用。
- 亚型间边界模糊及系统间分类不一致影响可重复性。
- 同一肿瘤内不同组织形态区域的分子亚型常不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular subtyping has been a major focus of bladder cancer research over the past decade. Despite many promising associations with clinical outcomes and treatment response, its clinical impact has yet to be defined. As part of the 2022 International Society of Urological Pathology Conference on Bladder Cancer, we reviewed the current state of the science for bladder cancer molecular subtyping. Our review included several different subtyping systems. We derived the following 7 principles, which summarize progress and challenges of molecular subtyping: (1) bladder cancer has 3 major molecular subtypes: luminal, basal-squamous, and neuroendocrine; (2) signatures of the tumor microenvironment differ greatly among bladder cancers, particularly among luminal tumors; (3) luminal bladder cancers are biologically diverse, and much of this diversity results from differences in features unrelated to the tumor microenvironment, such as FGFR3 signaling and RB1 inactivation; (4) molecular subtype of bladder cancer associates with tumor stage and histomorphology; (5) many subtyping systems include idiosyncrasies, such as subtypes recognized by no other system; (6) there are broad fuzzy borders between molecular subtypes, and cases that fall on these fuzzy borders are often classified differently by different subtyping systems; and (7) when there are histomorphologically distinct regions within a single tumor, the molecular subtypes of these regions are often discordant. We reviewed several use cases for molecular subtyping, highlighting their promise as clinical biomarkers. Finally, we conclude that data are currently insufficient to support the routine use of molecular subtyping to guide bladder cancer management, an opinion shared with the majority of conference attendees. We also conclude that molecular subtype should not be considered an "intrinsic" property of a tumor but should instead be considered the result of a specific laboratory test, performed using a specific testing platform and classification algorithm, validated for a specific clinical application.
引用
- Warrick JI, Al-Ahmadie H, Berman DM, et al. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility. Am J Surg Pathol. 2023. PMID: 37199442. doi:10.1097/PAS.0000000000002053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。